177210-33-2 Usage
General Description
5-Hydroxy-2H-1,4-benzoxazin-3(4H)-one, often abbreviated as HBOA, is an organic compound that belongs to the group of hydroxamic acids. It is a degradation product of 2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one, known as DIMBOA, which is found in several plants of the family Poaceae, including wheat and maize. HBOA plays a significant role in plant defense, exhibiting significant antifungal properties. The compound is a pale yellow solid, and its chemical properties have been studied for potential pharmaceutical applications. It is relatively stable, non-toxic, and has been shown to have various bioactive aspects, including acting as an antibiotic.
Check Digit Verification of cas no
The CAS Registry Mumber 177210-33-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,7,2,1 and 0 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 177210-33:
(8*1)+(7*7)+(6*7)+(5*2)+(4*1)+(3*0)+(2*3)+(1*3)=122
122 % 10 = 2
So 177210-33-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H7NO3/c10-5-2-1-3-6-8(5)9-7(11)4-12-6/h1-3,10H,4H2,(H,9,11)
177210-33-2Relevant articles and documents
PRMT5 INHIBITORS AND USES THEREOF
-
Paragraph 0434-0435, (2019/04/05)
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists
Weichert, Dietmar,Stanek, Markus,Hübner, Harald,Gmeiner, Peter
, p. 2641 - 2653 (2016/06/08)
Aiming to discover dual-acting β2 adrenergic/dopamine D2 receptor ligands, a structure-guided approach for the evolution of GPCR agonists that address multiple targets was elaborated. Starting from GPCR crystal structures, we describ
PRMT5 INHIBITORS AND USES THEREOF
-
Paragraph 00326, (2014/07/08)
Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical com-positions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.